v3.22.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Operating activities:    
Net loss $ (132,596) $ (72,435)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization expense 9,621 3,351
Amortization of financing lease right-of-use asset, related party 219 19
Amortization of interest on securities 638 329
Non-cash interest expense 0 205
Net realized loss (gain) on investments 66 0
Non-cash lease expense 478 671
Settlement of interest on debt 0 (1,235)
(Benefit) expense from deferred income taxes 1,760 (5,777)
Stock-based compensation 22,417 9,719
Provision for bad debt expense 649 0
Gain on forgiveness of PPP Loan 0 (1,775)
Loss on debt extinguishment 0 1,480
Cost of leased equipment sold to customer 204 568
Client warranty exchange of fixed asset 0 539
Change in fair value of contingent consideration 316 66
Changes in operating assets and liabilities (net of assets acquired and liabilities assumed in acquisition)    
Accounts receivable (2,900) (493)
Inventory (23,676) (15,928)
Prepaid expenses and other current assets (3,197) (1,324)
Other assets (1,130) (647)
Accounts payable 1,949 6,781
Accrued expenses and contract liabilities 366 3,959
Net cash used in operating activities (124,816) (71,927)
Investing activities:    
BioDiscovery acquisition, return of purchase consideration from escrow 694 0
Purchases of property and equipment (2,408) (822)
Sale of property and equipment 26 0
Construction in process (792) (638)
Purchases of intangible assets (102) 0
Payment of initial direct costs on lease 0 (607)
Purchase of available for sale securities (84,195) (313,392)
Sale and maturities of available for sale securities 200,888 86,483
Net cash provided by (used in) investing activities 82,767 (278,062)
Financing activities:    
Repayment of term-loan debt 0 (15,000)
Principal payments of financing lease liability, related party (36) (5)
Proceeds from PPP Loan 0 0
Proceeds from sale of common stock 23,128 342,711
Offering expenses on sale of common stock (578) (1,704)
Proceeds from sale of common stock under employee stock purchase plan 150 89
Proceeds from warrant and option exercises 343 10,020
Net cash provided by financing activities 23,007 336,111
Effect of exchange rates on cash, cash equivalents and restricted cash (38) 0
Net increase (decrease) in cash, cash equivalents and restricted cash (19,080) (13,878)
Cash, cash equivalents and restricted cash at beginning of period 24,571 38,449
Cash, cash equivalents and restricted cash at end of period 5,491 24,571
Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the total amounts reported on the consolidated statements of cash flows    
Cash and cash equivalents 5,091 24,571
Restricted cash 400 0
Total cash, cash equivalents and restricted cash at end of period 5,491 24,571
Supplemental disclosure of cash flow information    
Cash paid for interest 298 1,910
Cash paid for operating lease liabilities 1,622 447
Supplemental disclosure of non-cash financing and investing activity    
Fair value of common stock issued related to BioDiscovery acquisition 0 14,159
Operating lease liabilities resulting from obtaining and modifying right-of-use assets 517 4,751
Transfer of instruments and servers from inventory into property and equipment, net 7,244 6,857
Property and equipment included in accounts payable 90 0
Forgiveness of PPP Loan 0 1,775
Stock issued for services 0 15
Warrant exercise pursuant to cashless exercise 0 129
BioDiscovery    
Investing activities:    
Acquisition, net of cash acquired 0 (49,086)
Supplemental disclosure of non-cash financing and investing activity    
Contingent consideration related to BioDiscovery acquisition 0 9,000
Purigen acquisition    
Investing activities:    
Acquisition, net of cash acquired (31,344) 0
Supplemental disclosure of non-cash financing and investing activity    
Contingent consideration related to BioDiscovery acquisition $ 12,970 $ 0